{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:24:59Z","timestamp":1792081499814,"version":"4.4.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tenofovir, used for HIV-1 pre-exposure prophylaxis, HIV-1 treatment, and hepatitis B virus (HBV) treatment, is available as the prodrugs tenofovir disoproxil fumarate and tenofovir alafenamide. Tenofovir alafenamide has demonstrated improved renal safety and noninferior efficacy versus tenofovir disoproxil fumarate. This study synthesized evidence on tenofovir disoproxil fumarate and tenofovir alafenamide renal outcomes when used for pre-exposure prophylaxis and treating HIV-1, HBV, and HIV-1\/HBV coinfection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A systematic search for studies of pre-exposure prophylaxis and treatment of HIV-1, HBV, and HIV-1\/HBV coinfection was conducted in PubMed, EMBASE, Web of Science, and Cochrane Trial Registry from 2017 to 2025 for randomized controlled trials and from 2015 to 2025 for observational cohort studies. Additional randomized controlled trials were identified from a published systematic review. Renal outcomes included changes in estimated glomerular filtration rate, serum creatinine, and biomarkers for proteinuria. A random-effects model was used for meta-analysis. Heterogeneity was assessed using the I\n                      <jats:sup>2<\/jats:sup>\n                      test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty articles (35 randomized controlled trials, 5 observational cohort studies) involving 40,736 participants were included. Pooled estimates of 34 articles showed a statistically significant increase in estimated glomerular filtration rate change with tenofovir alafenamide (2.23 mL\/min, 95% confidence interval [CI] 0.98 to 3.48; I\n                      <jats:sup>2<\/jats:sup>\n                      94.06%) versus tenofovir disoproxil fumarate. Tenofovir alafenamide was associated with a slightly smaller increase in serum creatinine change (\u20130.02\u00a0mg\/dL, 95% CI \u22120.03 to \u22120.01; I\n                      <jats:sup>2<\/jats:sup>\n                      92.2%) versus tenofovir disoproxil fumarate across 24 articles. Tenofovir alafenamide was associated with significantly fewer occurrences of proteinuria and albuminuria compared with tenofovir disoproxil fumarate, with the differences becoming increasingly pronounced over time.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tenofovir alafenamide\u2013containing regimens were associated with improved renal safety outcomes over tenofovir disoproxil fumarate\u2013containing regimens across indications. Clinical benefits were more pronounced with longer follow-up durations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04628-9","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:15:05Z","timestamp":1763738105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of tenofovir alafenamide\u2013 versus tenofovir disoproxil fumarate\u2013containing regimens on renal outcomes: systematic literature review and meta-analysis"],"prefix":"10.1186","author":[{"given":"Xi","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Yun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeseon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Dhippayom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy R.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"4628_CR1","unstructured":"Centers for Disease Control and Prevention. US public health service: preexposure prophylaxis for the prevention of HIV infection in the United States \u2013 2021 update, a clinical practice guideline. https:\/\/stacks.cdc.gov\/view\/cdc\/112360. Accessed 22 Nov 2024."},{"key":"4628_CR2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"4628_CR3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.","journal-title":"J Hepatol"},{"key":"4628_CR4","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. 2024. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf. Accessed 17 Oct 2024."},{"key":"4628_CR5","unstructured":"Gilead Sciences, Inc. Viread\u00ae (tenofovir disoproxil fumarate): highlights of prescribing information. 2019. https:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liver-disease\/viread\/viread_pi.pdf. Accessed 22 Nov 2024."},{"key":"4628_CR6","unstructured":"Gilead Sciences, Inc. Truvada\u00ae (emtricitabine and tenofovir disoproxil fumarate): highlights of prescribing information. 2024. https:\/\/www.gilead.com\/~\/media\/files%20\/pdfs\/medicines\/hiv\/truvada\/truvada_pi.pdf. Accessed 22 Nov 2024."},{"key":"4628_CR7","unstructured":"HIV.gov. Tenofovir alafenamide \u2013 drug information. 2024. https:\/\/clinicalinfo.hiv.gov\/en\/drugs\/tenofovir-alafenamide\/patient. Accessed 18 Jul 2024."},{"key":"4628_CR8","unstructured":"Vemlidy. Package insert. Gilead Sciences, Inc.; 2024."},{"key":"4628_CR9","unstructured":"Descovy. Package insert. Gilead Sciences, Inc.; 2019."},{"key":"4628_CR10","unstructured":"Biktarvy. Package insert. Gilead Sciences, Inc.; 2021."},{"key":"4628_CR11","unstructured":"World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015. https:\/\/www.who.int\/publications\/i\/item\/9789241549059. Accessed 22 Nov 2024."},{"key":"4628_CR12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","volume":"15","author":"G Lau","year":"2021","unstructured":"Lau G, Yu ML, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021;15:1031\u201348.","journal-title":"Hepatol Int"},{"key":"4628_CR13","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1097\/QAD.0b013e328339fe53","volume":"24","author":"A Mocroft","year":"2010","unstructured":"Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667\u201378.","journal-title":"AIDS"},{"key":"4628_CR14","doi-asserted-by":"crossref","first-page":"e66223","DOI":"10.1371\/journal.pone.0066223","volume":"8","author":"P Morlat","year":"2013","unstructured":"Morlat P, Vivot A, Vandenhende MA, et al. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004\u20132012. PLoS ONE. 2013;8:e66223.","journal-title":"PLoS ONE"},{"key":"4628_CR15","first-page":"817","volume":"19","author":"WDF Venter","year":"2018","unstructured":"Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med. 2018;19:817.","journal-title":"South Afr J HIV Med"},{"key":"4628_CR16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2011.01.022","volume":"57","author":"AM Hall","year":"2011","unstructured":"Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773\u201380.","journal-title":"Am J Kidney Dis"},{"key":"4628_CR17","first-page":"135965352110676","volume":"27","author":"WA Lee","year":"2022","unstructured":"Lee WA, Cheng AK. Tenofovir alafenamide fumarate. Antivir Ther. 2022;27:13596535211067600.","journal-title":"Antivir Ther"},{"key":"4628_CR18","first-page":"1315","volume":"14","author":"X Li","year":"2021","unstructured":"Li X, Tan XY, Cui XJ, Yang M, Chen C, Chen XY. Pharmacokinetics of tenofovir alafenamide fumarate and tenofovir in the Chinese people: effects of non-genetic factors and genetic variations. Pharmgenomics Pers Med. 2021;14:1315\u201329.","journal-title":"Pharmgenomics Pers Med"},{"key":"4628_CR19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/QAD.0b013e3283262a64","volume":"23","author":"P Labarga","year":"2009","unstructured":"Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689\u201396.","journal-title":"AIDS"},{"key":"4628_CR20","doi-asserted-by":"crossref","first-page":"e5146","DOI":"10.1097\/MD.0000000000005146","volume":"95","author":"H Wang","year":"2016","unstructured":"Wang H, Lu X, Yang X, Xu N. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis. Medicine (Baltimore). 2016;95:e5146.","journal-title":"Med (Baltim)"},{"key":"4628_CR21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijid.2020.01.035","volume":"93","author":"X Tao","year":"2020","unstructured":"Tao X, Lu Y, Zhou Y, Zhang L, Chen Y. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Int J Infect Dis. 2020;93:108\u201317.","journal-title":"Int J Infect Dis"},{"key":"4628_CR22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672\u201381.","journal-title":"J Hepatol"},{"key":"4628_CR23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","volume":"119","author":"HLY Chan","year":"2024","unstructured":"Chan HLY, Buti M, Lim YS, et al. Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol. 2024;119:486\u201396.","journal-title":"Am J Gastroenterol"},{"key":"4628_CR24","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"4628_CR25","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/QAD.0000000000002223","volume":"33","author":"SK Gupta","year":"2019","unstructured":"Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019;33:1455\u201365.","journal-title":"AIDS"},{"key":"4628_CR26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2055-6640(20)30248-X","volume":"4","author":"A Hill","year":"2018","unstructured":"Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety? J Virus Erad. 2018;4:72\u20139.","journal-title":"J Virus Erad"},{"key":"4628_CR27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"4628_CR28","unstructured":"Deeks JJ, Higgins JPT, Altman DG, editors. 9.5.2 Identifying and measuring heterogeneity. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2023. https:\/\/handbook-5-1.cochrane.org\/chapter_9\/9_5_2_identifying_and_measuring_heterogeneity.htm. Accessed 9 Jul 2024."},{"key":"4628_CR29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"4628_CR30","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jama.2014.8166","volume":"312","author":"A Dechartres","year":"2014","unstructured":"Dechartres A, Altman DG, Trinquart L, Boutron I, Ravaud P. Association between analytic strategy and estimates of treatment outcomes in meta-analyses. JAMA. 2014;312:623\u201330.","journal-title":"JAMA"},{"key":"4628_CR31","unstructured":"Holger J, Sch\u00fcnemann JPH, Visit GE, et al. Completing \u2018summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. The Cochrane Collaboration; 2024. Accessed 22 Jul 2024. https:\/\/training.cochrane.org\/handbook\/current\/chapter-14."},{"key":"4628_CR32","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1016\/S2352-3018(16)00024-2","volume":"3","author":"JE Gallant","year":"2016","unstructured":"Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3:e158\u201365.","journal-title":"Lancet HIV"},{"key":"4628_CR33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","volume":"67","author":"PE Sax","year":"2014","unstructured":"Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67:52\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4628_CR34","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","volume":"385","author":"PE Sax","year":"2015","unstructured":"Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606\u201315.","journal-title":"Lancet"},{"key":"4628_CR35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000000618","volume":"69","author":"A Mills","year":"2015","unstructured":"Mills A, Crofoot G Jr, McDonald C, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2015;69:439\u201345.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4628_CR36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","volume":"396","author":"KH Mayer","year":"2020","unstructured":"Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396:239\u201354.","journal-title":"Lancet"},{"key":"4628_CR37","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S2352-3018(21)00071-0","volume":"8","author":"O Ogbuagu","year":"2021","unstructured":"Ogbuagu O, Ruane PJ, Podzamczer D, et al. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2021;8:e397\u2013407.","journal-title":"Lancet HIV"},{"key":"4628_CR38","doi-asserted-by":"crossref","unstructured":"Byun KS, Choi J, Kim JH et al. Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate. Clin Gastroenterol Hepatol. 2022;20:427 \u201337.e5.","DOI":"10.1016\/j.cgh.2021.04.045"},{"key":"4628_CR39","doi-asserted-by":"crossref","first-page":"e0251552","DOI":"10.1371\/journal.pone.0251552","volume":"16","author":"CQ Pan","year":"2021","unstructured":"Pan CQ, Chang TT, Bae SH, et al. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. PLoS ONE. 2021;16:e0251552.","journal-title":"PLoS ONE"},{"key":"4628_CR40","doi-asserted-by":"crossref","unstructured":"Eron JJ, Orkin C, Cunningham D et al. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine\/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide (D\/C\/F\/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Antiviral Res. 2019;170:104543.","DOI":"10.1093\/ofid\/ofy209.153"},{"key":"4628_CR41","doi-asserted-by":"crossref","first-page":"e0226276","DOI":"10.1371\/journal.pone.0226276","volume":"14","author":"L Hermansson","year":"2019","unstructured":"Hermansson L, Yilmaz A, Price RW, et al. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS ONE. 2019;14:e0226276.","journal-title":"PLoS ONE"},{"key":"4628_CR42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/QAD.0000000000002463","volume":"34","author":"C Orkin","year":"2020","unstructured":"Orkin C, Eron JJ, Rockstroh J, et al. Week 96 results of a phase 3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2020;34:707\u201318.","journal-title":"AIDS"},{"key":"4628_CR43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/aid.2017.0203","volume":"34","author":"E DeJesus","year":"2018","unstructured":"DeJesus E, Haas B, Segal-Maurer S, et al. Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate- to a tenofovir alafenamide-based regimen through 96 weeks of treatment. AIDS Res Hum Retroviruses. 2018;34:337\u201342.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"4628_CR44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAI.0000000000002137","volume":"82","author":"C Kityo","year":"2019","unstructured":"Kityo C, Hagins D, Koenig E, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial. J Acquir Immune Defic Syndr. 2019;82:321\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4628_CR45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/QAI.0000000000001663","volume":"78","author":"S Hodder","year":"2018","unstructured":"Hodder S, Squires K, Kityo C, et al. Brief report: efficacy and safety of switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E\/C\/F\/TAF) in virologically suppressed women. J Acquir Immune Defic Syndr. 2018;78:209\u201313.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4628_CR46","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1016\/S2352-3018(19)30195-X","volume":"6","author":"F Maggiolo","year":"2019","unstructured":"Maggiolo F, Rizzardini G, Raffi F, et al. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. Lancet HIV. 2019;6:e655\u201366.","journal-title":"Lancet HIV"},{"key":"4628_CR47","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"WDF Venter","year":"2020","unstructured":"Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7:e666\u201376.","journal-title":"Lancet HIV"},{"key":"4628_CR48","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/hiv.12664","volume":"19","author":"D Hagins","year":"2018","unstructured":"Hagins D, Orkin C, Daar ES, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med. 2018;19:724\u201333.","journal-title":"HIV Med"},{"key":"4628_CR49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","volume":"5","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Buti M, Fung S, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020;5:441\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4628_CR50","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381:803\u201315.","journal-title":"N Engl J Med"},{"key":"4628_CR51","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/QAD.0000000000001817","volume":"32","author":"JJ Eron","year":"2018","unstructured":"Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018;32:1431\u201342.","journal-title":"AIDS"},{"key":"4628_CR52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAI.0000000000001350","volume":"75","author":"JR Arribas","year":"2017","unstructured":"Arribas JR, Thompson M, Sax PE, et al. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E\/C\/F) for initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr. 2017;75:211\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4628_CR53","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/QAI.0000000000001344","volume":"75","author":"F Raffi","year":"2017","unstructured":"Raffi F, Orkin C, Clarke A, et al. Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults. J Acquir Immune Defic Syndr. 2017;75:226\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4628_CR54","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185\u201395.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4628_CR55","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4628_CR56","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S2352-3018(17)30032-2","volume":"4","author":"E DeJesus","year":"2017","unstructured":"DeJesus E, Ramgopal M, Crofoot G, et al. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017;4:e205\u201313.","journal-title":"Lancet HIV"},{"key":"4628_CR57","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/S2352-3018(17)30031-0","volume":"4","author":"C Orkin","year":"2017","unstructured":"Orkin C, DeJesus E, Ramgopal M, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017;4:e195\u2013204.","journal-title":"Lancet HIV"},{"key":"4628_CR58","first-page":"324","volume":"9","author":"J Hou","year":"2021","unstructured":"Hou J, Ning Q, Duan Z, et al. 3-year treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for chronic HBV infection in China. J Clin Transl Hepatol. 2021;9:324\u201334.","journal-title":"J Clin Transl Hepatol"},{"key":"4628_CR59","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","volume":"10","author":"A Avihingsanon","year":"2023","unstructured":"Avihingsanon A, Lu H, Leong CL, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. Lancet HIV. 2023;10:e640\u201352.","journal-title":"Lancet HIV"},{"key":"4628_CR60","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/QAI.0000000000000940","volume":"72","author":"D Wohl","year":"2016","unstructured":"Wohl D, Oka S, Clumeck N, et al. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016;72:58\u201364.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4628_CR61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","volume":"16","author":"A Mills","year":"2016","unstructured":"Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016;16:43\u201352.","journal-title":"Lancet Infect Dis"},{"key":"4628_CR62","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/ciae012","volume":"79","author":"R Wang","year":"2024","unstructured":"Wang R, Sun L, Wang X, et al. Rapid initiation of antiretroviral therapy with coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus efavirenz, lamivudine, and tenofovir disoproxil fumarate in HIV-positive men who have sex with men in China: week 48 results of the multicenter, randomized clinical trial. Clin Infect Dis. 2024;79:169\u201376.","journal-title":"Clin Infect Dis"},{"key":"4628_CR63","first-page":"101143","volume":"49","author":"F Zhang","year":"2024","unstructured":"Zhang F, Wu H, Cai W, et al. Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial. Lancet Reg Health West Pac. 2024;49:101143.","journal-title":"Lancet Reg Health West Pac"},{"key":"4628_CR64","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(21)00314-7","volume":"397","author":"S Lockman","year":"2021","unstructured":"Lockman S, Brummel SS, Ziemba L, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010\/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2021;397:1276\u201392.","journal-title":"Lancet"},{"key":"4628_CR65","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3350\/cmh.2021.0314","volume":"28","author":"J Jeong","year":"2022","unstructured":"Jeong J, Shin JW, Jung SW, Park EJ, Park NH. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis. Clin Mol Hepatol. 2022;28:254\u201364.","journal-title":"Clin Mol Hepatol"},{"key":"4628_CR66","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/liv.15086","volume":"42","author":"SH Kim","year":"2022","unstructured":"Kim SH, Cho EJ, Jang BO, et al. Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection. Liver Int. 2022;42:320\u20139.","journal-title":"Liver Int"},{"key":"4628_CR67","doi-asserted-by":"crossref","first-page":"ofad695","DOI":"10.1093\/ofid\/ofad695","volume":"11","author":"AS Rivera","year":"2024","unstructured":"Rivera AS, Pak K, Mefford MT, Hechter RC. Changes in glomerular filtration rate after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate for human immunodeficiency virus preexposure prophylaxis. Open Forum Infect Dis. 2024;11:ofad695.","journal-title":"Open Forum Infect Dis"},{"key":"4628_CR68","doi-asserted-by":"crossref","first-page":"21656","DOI":"10.1038\/s41598-024-72986-9","volume":"14","author":"X Wu","year":"2024","unstructured":"Wu X, Yan Q, Jiang C, Fan R, Li S. Real-world study on the efficacy and safety of different treatment regimens in treatment-naive CHB patients with high viral load. Sci Rep. 2024;14:21656.","journal-title":"Sci Rep"},{"key":"4628_CR69","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.livres.2024.10.001","volume":"8","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Xu W, Deng Z, et al. Long-term efficacy and safety of tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir in treating hepatitis B virus-related acute-on-chronic liver failure: a 144-week data analysis. Liver Res. 2024;8:295\u2013303.","journal-title":"Liver Res"},{"key":"4628_CR70","doi-asserted-by":"crossref","unstructured":"Gane E, George B, Munn S, Wang H, Suri V, Gaggar A. Jul. Renal and bone safety in post liver transplant patients with chronic kidney disease receiving tenofovir alafenamide for HBV prophylaxis [abstract]. Presented at: American Transplant Congress; 2\u20136 Jun 2018; Seattle, WA. https:\/\/atcmeetingabstracts.com\/abstract\/renal-and-bone-safety-in-post-liver-transplant-patients-with-chronic-kidney-disease-receiving-tenofovir-alafenamide-for-hbv-prophylaxis\/. Accessed 16 Jul 2024.","DOI":"10.1016\/S0168-8278(18)31276-5"},{"key":"4628_CR71","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/QAD.0000000000000103","volume":"28","author":"JC Yombi","year":"2014","unstructured":"Yombi JC, Pozniak A, Boffito M, et al. Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS. 2014;28:621\u201332.","journal-title":"AIDS"},{"key":"4628_CR72","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/hiv.12784","volume":"20","author":"JL Casado","year":"2019","unstructured":"Casado JL, Monsalvo M, Vizcarra P, Fontecha M, Serrano-Villar S, Moreno S. Evaluation of kidney function in HIV-infected patients receiving an antiretroviral regimen containing one or two inhibitors of the tubular secretion of creatinine. HIV Med. 2019;20:648\u201356.","journal-title":"HIV Med"},{"key":"4628_CR73","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1016\/S2352-3018(22)00004-2","volume":"9","author":"R Schaefer","year":"2022","unstructured":"Schaefer R, Amparo da Costa Leite PH, Silva R, et al. Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data. Lancet HIV. 2022;9:e242\u201353.","journal-title":"Lancet HIV"},{"key":"4628_CR74","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1214234","volume":"369","author":"MG Shlipak","year":"2013","unstructured":"Shlipak MG, Matsushita K, Arnlov J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369:932\u201343.","journal-title":"N Engl J Med"},{"key":"4628_CR75","doi-asserted-by":"crossref","unstructured":"Delgado C, Baweja M, Crews DC et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79:268\u201388.e1.","DOI":"10.1053\/j.ajkd.2021.08.003"},{"key":"4628_CR76","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C\u2013based equations to estimate GFR without race. N Engl J Med. 2021;385:1737\u201349.","journal-title":"N Engl J Med"},{"key":"4628_CR77","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1681\/ASN.2014060607","volume":"26","author":"L Fan","year":"2015","unstructured":"Fan L, Levey AS, Gudnason V, et al. Comparing GFR estimating equations using cystatin C and creatinine in elderly individuals. J Am Soc Nephrol. 2015;26:1982\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"4628_CR78","doi-asserted-by":"crossref","first-page":"100628","DOI":"10.1016\/j.xkme.2023.100628","volume":"5","author":"OA Potok","year":"2023","unstructured":"Potok OA, Rifkin DE, Ix JH, et al. Estimated GFR accuracy when cystatin C\u2013 and creatinine-based estimates are discrepant in older adults. Kidney Med. 2023;5:100628.","journal-title":"Kidney Med"},{"key":"4628_CR79","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1086\/424013","volume":"39","author":"LA Szczech","year":"2004","unstructured":"Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis. 2004;39:1199\u2013206.","journal-title":"Clin Infect Dis"},{"key":"4628_CR80","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1053\/j.ajkd.2010.05.019","volume":"56","author":"A Choi","year":"2010","unstructured":"Choi A, Scherzer R, Bacchetti P, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis. 2010;56:872\u201382.","journal-title":"Am J Kidney Dis"},{"key":"4628_CR81","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QAI.0b013e3181cc1070","volume":"55","author":"CM Wyatt","year":"2010","unstructured":"Wyatt CM, Hoover DR, Shi Q, et al. Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr. 2010;55:73\u20137.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4628_CR82","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/cid\/ciu734","volume":"59","author":"A Mweemba","year":"2014","unstructured":"Mweemba A, Zanolini A, Mulenga L, et al. Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults. Clin Infect Dis. 2014;59:1757\u201360.","journal-title":"Clin Infect Dis"},{"key":"4628_CR83","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64:821\u201335.","journal-title":"Am J Kidney Dis"},{"key":"4628_CR84","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","volume":"311","author":"J Coresh","year":"2014","unstructured":"Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518\u201331.","journal-title":"JAMA"},{"key":"4628_CR85","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/apt.18278","volume":"60","author":"M Buti","year":"2024","unstructured":"Buti M, Lim YS, Chan HLY, et al. Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: final results from two randomised phase 3 trials. Aliment Pharmacol Ther. 2024;60:1573\u201386.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04628-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04628-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04628-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:19:45Z","timestamp":1781615985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-025-04628-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":85,"alternative-id":["4628"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04628-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; this systematic literature review did not involve human participant data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable; this systematic literature review did not contain data from any individual person.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"X.L., K.Y.P., H.Le., H.Li., C.W., and N.C. received institutional grant funding from Gilead Sciences, Inc. T.D. has no disclosures to declare. R.R., A.R.W., and J.G. are employees and stockholders of Gilead Sciences, Inc. A.C. was an employee and stockholder of Gilead Sciences, Inc., at the time the study was conducted.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}